Clinical protocols used to inhibit the growth or spread of NEOPLASMS.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Precise and detailed plans for the study of a medical or biomedical problem and/or plans for a regimen of therapy.

Study on chemoprevention of hepatocellular carcinoma by ginseng: an introduction to the protocol. (1/58)

In patients with chronic hepatitis C virus disease, there is a high incidence of development of hepatocellular carcinoma (HCC) in the process of transition from chronic hepatitis to hepatic cirrhosis. Although ginseng traditionally has been used mainly as a nutritional supplement in Asian countries, a case-control study found that it may inhibit the development of HCC. We therefore planned a clinical study of HCC prevention by medicinal ginseng. The subjects are patients with chronic C virus disease (chronic hepatitis and hepatic cirrhosis), who are high risk group for HCC. This intervention study is a multi-center, double-blind, randomized controlled trial. The participants will be randomly divided into two groups. The test sample (1 g of red ginseng powder per day) will be administered for 5 yr, and ginseng intake will be prohibited during the administration period. The primary endpoint of this study is the development of HCC. Target number of recruiting subjects are 300. The participants should be registered from February 2001 to January 2003.  (+info)

Guidelines for the treatment of recurrent and metastatic cervical cancer. (2/58)

Although there have been important advances in the management of women with cervical cancer, the optimal treatment for patients with locally recurrent and metastatic disease is still problematic, and there are relatively few randomized trials to guide treatment decisions. This paper reviews the approach to management of patients who relapse after primary treatment for cervical cancer. Patients who are still potentially curable with radical treatment are identified, and the various treatment strategies are discussed. However, most women are treated with palliative intent, and the literature on palliative management is reviewed together with the levels of evidence.  (+info)

High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. (3/58)

OBJECTIVE: To identify patient characteristics associated with the development of local recurrence and the effect of local recurrence on subsequent morbidity and mortality in patients with intermediate- to high-grade extremity soft tissue sarcomas. SUMMARY BACKGROUND DATA: Numerous studies on extremity soft tissue sarcomas have consistently shown that presentation with locally recurrent disease is associated with the development of subsequent local recurrences and that large tumor size and high histologic grade are significant factors associated with decreased survival. However, the effect of local recurrence on patient survival remains unclear. METHODS: From 1975 to 1997, 753 patients with intermediate- to high-grade extremity soft tissue sarcomas were treated at UCLA. Treatment outcomes and patient characteristics were analyzed to identify factors associated with both local recurrence and survival. RESULTS: Patients with locally recurrent disease were at a significantly increased risk of developing a subsequent local recurrence. Local recurrence was a morbid event requiring amputation in 38% of the cases. The development of a local recurrence was the most significant factor associated with decreased survival. Once a patient developed a local recurrence, he or she was about three times more likely to die of disease compared to similar patients who had not developed a local recurrence. CONCLUSIONS: Local recurrence in patients with intermediate- to high-grade extremity soft tissue sarcomas is associated with the development of subsequent local recurrences, a morbid event decreasing functional outcomes and the most significant factor associated with decreased survival. Although 85% to 90% of patients with high-grade extremity soft tissue sarcomas are treatable with a limb salvage approach, patients who develop a local recurrence need aggressive treatment and should be considered for trials of adjuvant systemic therapy.  (+info)

Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. (4/58)

BACKGROUND: In primary central high-grade osteosarcoma, a number of distinct subtypes have been identified, but little is known about the response to chemotherapy. METHODS: The authors investigated whether the subtypes correlated with histologic response to chemotherapy in 1058 patients with osteosarcoma of the extremities who were treated with neoadjuvant chemotherapy over the last 20 years. The tumors were classified as osteoblastic (70%), chondroblastic (13%), fibroblastic (9%), and telangiectatic (6%). At diagnosis, 911 patients had localized disease and 147 had resectable lung metastases. RESULTS: The response to preoperative chemotherapy was good (90% or more tumor necrosis) in 59% of patients and poor (< 90% tumor necrosis) in 41% of patients. The rate of good responses was significantly higher (P = 0.0001) in the fibroblastic (83%) and telangiectatic (80%) tumors and significantly lower in chondroblastic tumors (43%). Prognosis was significantly correlated with the histologic subtypes. The 5-year overall survival rate was significantly higher (P = 0.0001) in fibroblastic (83%) and telangiectatic (75%) tumors than in osteoblastic (62%) and chondroblastic (60%) tumors. In all subtypes, except for the chondroblastic subtype, the 5-year overall survival rate was significantly higher (P = 0.0001) in good responders P = 0.0001 (68%) than in poor responders (52%). CONCLUSIONS: The authors concluded that the histologic subtype of primary central high-grade osteosarcoma of the extremity was strictly correlated with histologic response to chemotherapy and probably, as a consequence, also with prognosis. Further studies are needed to establish whether these results justify a specific therapeutic approach based on the histologic subtype of the tumor.  (+info)

The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience. (5/58)

To examine the influence of the pathology review mechanism on the results of analyses of therapeutic efficacy and biological prognostic correlates for pediatric high-grade gliomas, we evaluated the effects of using single-expert review or consensus review, as alternatives to institutional classification, in determining outcome results of a large randomized trial. The study group was the randomized cohort of Children's Cancer Group study 945, which compared efficacy of 2 chemotherapy regimens adjuvant to surgery and radiation. Trial eligibility required institutional histopathologic diagnosis of high-grade glioma. Sections of study tumors also were centrally reviewed, initially by a study review neuropathologist and subsequently by 5 neuropathologists, including the review pathologist. Reviews were independent, and reviewers were masked to clinical factors and outcomes, and consensus diagnoses of the panel were then established. Among 172 eligible patients, 42 tumors were classified as discordant on single-expert review and 51 on consensus review. Progression-free survival probabilities calculated for patients with tumors classified as high-grade gliomas by either single-expert or consensus review were inferior to those for the overall, institutionally diagnosed cohort. However, conclusions of the study regarding relative efficacy of treatment and clinical and molecular outcome correlates were unaffected by diagnosis method. Resection extent, proliferation index, and p53 expression were associated strongly with outcome, regardless of diagnosis method. However, comparisons between arms in which inclusion was determined by different review criteria for each arm caused spurious conclusions about efficacy differences between treatments. We conclude that the pathology review mechanism had little effect on within-trial comparisons of therapeutic effects or prognostic correlates in this randomized study, but strongly influenced survival distributions that were calculated for each treatment arm. These results support the implementation of expedited central review in therapeutic studies involving childhood malignant gliomas as a way to prospectively identify and exclude cases with discordant diagnoses and indicate the need for additional measures, such as molecular assessments, to increase the reproducibility of neuropathologic classification for these tumors.  (+info)

Implementing clinical protocols in oncology: quality gaps and the learning curve phenomenon. (6/58)

BACKGROUND: The quality improvement effort in clinical practice has focused mostly on 'performance quality', i.e. on the development of comprehensive, evidence-based guidelines. This study aimed to assess the 'conformance quality', i.e. the extent to which guidelines once developed are correctly and consistently applied. It also aimed to assess the existence of quality gaps in the treatment of certain patient segments as defined by age or gender and to investigate methods to improve overall conformance quality. METHODS: A retrospective audit of clinical practice in a well-defined oncology setting was undertaken and the results compared to those obtained from prospectively applying an internally developed clinical protocol in the same setting and using specific tools to increase conformance quality. RESULTS: All indicators showed improvement after the implementation of the protocol that in many cases reached statistical significance, while in the entire cohort advanced age was associated (although not significantly) with sub-optimal delivery of care. A 'learning curve' phenomenon in the implementation of quality initiatives was detected, with all indicators improving substantially in the second part of the prospective study. CONCLUSIONS: Clinicians should pay separate attention to the implementation of chosen protocols and employ specific tools to increase conformance quality in patient care.  (+info)

Probabilistic reporting of EUS-FNA cytology: Toward improved communication and better clinical decisions. (7/58)

BACKGROUND: The objectives of this study were to determine threshold probabilities needed to perform endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) and those needed to treat patients suspected of having malignancy and then to compare these thresholds to the pre- and posttest probabilities of malignancy associated with benign, atypical, suspicious, and malignant diagnoses. The goal was to aid endoscopists in making appropriate clinical decisions based on both quantitative and qualitative approaches. METHODS: The study included 633 consecutive patients. A decision tree was constructed to estimate the "treatment" threshold. Using treatment threshold and likelihood ratios, the authors determined the "no-test-test" and "test-treatment" thresholds. Pretest probability was compared with no-test-test and test-treatment thresholds, and the post-EUS-FNA probability of malignancy for each diagnostic category with the treatment threshold. Results were stratified by lesion site, lesion size, and cytopathologist. RESULTS: EUS-FNA has a wide range of pretest probabilities within which it could be performed (0.06-0.98). The posttest probabilities for malignancy, 0.99 (95% confidence interval [CI], 0.967-0.996) and 0.09 (95% CI, 0.057-0.126), after a positive or a negative result, respectively, were significantly different from the treatment threshold but not those of suspicious, 0.92 (95% CI, 0.767-0.994) diagnosis. The posttest probability of atypical diagnosis, 0.60 (95% CI, 0.407-0.772), was not significantly different from that of pretest probability. Results did not vary by lesion size, organ site, or cytopathologist. CONCLUSION: The authors demonstrated the uncertainty associated with EUS-FNA diagnostic categories and used the threshold approach to qualify quantitatively the decision to perform EUS-FNA and the decision to treat patients suspected of having malignancy.  (+info)

Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol. (8/58)

BACKGROUND: Adjuvant chemotherapy has been proven to be beneficial for patients with early stage non-small cell lung cancer. However, toxicity and insufficient dose delivery have been critical issues with the chemotherapy used. Doublet regimens with pemetrexed, a multi-target folate inhibitor, and platin show clear activity in non-small cell lung cancer and are well tolerated with low toxicity rates and excellent delivery. METHODS/DESIGN: In this prospective, multi-center, open label randomized phase II study, patients with pathologically confirmed non-small cell lung cancer, stage IB, IIA, IIB, T3N1 will be randomized after complete tumor resection either to 4 cycles of the standard adjuvant vinorelbine and cisplatin regimen from the published phase III data, or to 4 cycles of pemetrexed 500 mg/m2 d1 and cisplatin 75 mg/m2 d1, q 3 weeks. Primary objective is to compare the clinical feasibility of these cisplatin doublets defined as non-occurrence of grade 4 neutropenia and/or thrombocytopenia > 7 days or bleeding, grade 3/4 febrile neutropenia and/or infection, grade 3/4 non-hematological toxicity, non-acceptance leading to premature withdrawal and no cancer or therapy related death. Secondary parameters are efficacy (time to relapse, overall survival) and drug delivery. Parameters of safety are hematologic and non-hematologic toxicity of both arms. DISCUSSION: The TREAT trial was designed to evaluate the clinical feasibility, i.e. rate of patients without dose limiting toxicities or premature treatment withdrawal or death of the combination of cisplatin and pemetrexed as well as the published phase III regimen of cisplatin and vinorelbine. Hypothesis of the study is that reduced toxicities might improve the feasibility of drug delivery, compliance and the convenience of treatment for the patient and perhaps survival.  (+info)

Antineoplastic protocols refer to the standardized treatment plans used in cancer therapy that involve the use of antineoplastic agents or drugs. These protocols are developed based on clinical research and evidence-based medicine, and they outline the specific types, dosages, schedules, and routes of administration of antineoplastic drugs for the treatment of various types of cancer.

The main goal of antineoplastic protocols is to optimize the effectiveness of cancer therapy while minimizing toxicity and adverse effects. They may involve single-agent or multi-agent chemotherapy, as well as other forms of cancer treatment such as radiation therapy, immunotherapy, and targeted therapy. Antineoplastic protocols are often individualized based on the patient's age, performance status, tumor type and stage, genetic makeup, and other factors that may affect their response to treatment.

It is important for healthcare providers to follow antineoplastic protocols carefully to ensure that patients receive safe and effective cancer therapy. Regular monitoring and assessment of the patient's response to treatment are also crucial components of antineoplastic protocols, as they allow healthcare providers to adjust the treatment plan as needed to maximize its benefits and minimize its risks.

Antineoplastic agents are a class of drugs used to treat malignant neoplasms or cancer. These agents work by inhibiting the growth and proliferation of cancer cells, either by killing them or preventing their division and replication. Antineoplastic agents can be classified based on their mechanism of action, such as alkylating agents, antimetabolites, topoisomerase inhibitors, mitotic inhibitors, and targeted therapy agents.

Alkylating agents work by adding alkyl groups to DNA, which can cause cross-linking of DNA strands and ultimately lead to cell death. Antimetabolites interfere with the metabolic processes necessary for DNA synthesis and replication, while topoisomerase inhibitors prevent the relaxation of supercoiled DNA during replication. Mitotic inhibitors disrupt the normal functioning of the mitotic spindle, which is essential for cell division. Targeted therapy agents are designed to target specific molecular abnormalities in cancer cells, such as mutated oncogenes or dysregulated signaling pathways.

It's important to note that antineoplastic agents can also affect normal cells and tissues, leading to various side effects such as nausea, vomiting, hair loss, and myelosuppression (suppression of bone marrow function). Therefore, the use of these drugs requires careful monitoring and management of their potential adverse effects.

Clinical protocols, also known as clinical practice guidelines or care paths, are systematically developed statements that assist healthcare professionals and patients in making decisions about the appropriate healthcare for specific clinical circumstances. They are based on a thorough evaluation of the available scientific evidence and consist of a set of recommendations that are designed to optimize patient outcomes, improve the quality of care, and reduce unnecessary variations in practice. Clinical protocols may cover a wide range of topics, including diagnosis, treatment, follow-up, and disease prevention, and are developed by professional organizations, government agencies, and other groups with expertise in the relevant field.

... antineoplastic combined chemotherapy protocols MeSH E02.190.044.080 - acupressure MeSH E02.190.044.105 - acupuncture analgesia ... antineoplastic combined chemotherapy protocols MeSH E02.319.162.150 - antibiotic prophylaxis MeSH E02.319.300.253 - delayed- ... antineoplastic combined chemotherapy protocols MeSH E02.319.310.075 - antiretroviral therapy, highly active MeSH E02.319. ...
... clinical protocols MeSH N05.715.360.775.225.500 - antineoplastic protocols MeSH N05.715.360.775.235 - clinical trials MeSH ...
The FLAMSA protocol is most often used as an induction part of a reduced-intensity conditioning regimen for patients eligible ... G-CSF is still included, even though the "G" is taken out of the acronym.) Amsacrine is an alkylating antineoplastic agent that ... November 1994). "FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of ' ... clinical protocols and preliminary results]". Deutsche Medizinische Wochenschrift (in German). 127 (42): 2186-92. doi:10.1055/s ...
Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in ... Antineoplastic and immunomodulating drug stubs). ...
Protocol DAR-312) of Darusentan in Resistant Hypertension (Darusentan)" at ClinicalTrials.gov v t e v t e (Articles with short ... Antineoplastic and immunomodulating drug stubs). ...
Nature Protocols, 5: 725-738, 2010. Y Zhang. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics, 9: 40, ... "Genotoxicity of the copper antineoplastic coordination complexes casiopeinas". Toxicology in Vitro. 25 (7): 1376-84. doi: ...
2015). "Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2 ... Cold Spring Harbor Protocols. 2016 (2): pdb.prot085118. doi:10.1101/pdb.prot085118. PMID 26832684. Sun R, Eriksson S, Wang L ( ... A standardized protocol that will help comparison of clinical studies has been suggested. Hybridomas are cells obtained by ... a biochemical strategy to enhance the activation of antineoplastic drugs". Puerto Rico Health Sciences Journal. 13 (1): 19-23. ...
Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial". JMIR Res Protoc. 9 (4): e16664. doi:10.2196/16664. ... Antineoplastic and immunomodulating drug stubs). ...
Previously one could only get it from the CDC for emergency use under an expanded access IND protocol for treatment of free- ... Initial in vivo investigation on the antineoplastic activity showed positive result, but then only at high dosage and at high ... Antineoplastic drugs, Antiprotozoal agents, Antiretroviral drugs, Antiviral drugs, Drugs acting on the blood and blood forming ... demonstrated that the antineoplastic activity of the phospholipid analogue miltefosine (at the time known as ...
... [Coordinated Undermining of Survival Paths] is one of several cancer treatment protocols using re-purposed older drugs to ... Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug ... CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, ...
"8.1.5: Other antineoplastic drugs". British National Formulary (BNF 57). United Kingdom: BMJ Group and RPS Publishing. March ... As researchers developed deeper into ASNase treatment protocols, it became evident that different preparations of the enzyme ... February 2007). "Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute ... These developments have significantly influenced treatment strategies and protocols, as evidenced by initiatives such as the ...
Alkylating antineoplastic agents, for example, cause DNA damage, which is more harmful to cancer cells than regular cells. ... Antiseptics, anesthesia, antibiotics, better surgical techniques, evidence-based protocols and best practices continue to be ...
May 2020). "A Smartphone App-Based Mindfulness Intervention for Cancer Survivors: Protocol for a Randomized Controlled Trial". ... "A Systematic Review of Adherence to Oral Antineoplastic Therapies". The Oncologist. 21 (3): 354-76. doi:10.1634/theoncologist. ... JMIR Research Protocols. 9 (5): e15178. doi:10.2196/15178. PMC 7248798. PMID 32390591. National Comprehensive Cancer Network ( ... become an increasingly important topic of study in psycho-oncology due to the advent and proliferation of oral antineoplastics ...
Hormonal antineoplastic drugs, Gonadotropin-releasing hormone and gonadotropins, Progonadotropins). ... secretion of an early discontinuation of gonadotrophin-releasing hormone agonist administration in short-term protocol for in- ...
The new protocol that he developed led to a marked increase in disease-free survival rates for patients with medulloblastoma, ... Cisplatin is in the platinum-based antineoplastic family of medications. It works in part by binding to DNA and inhibiting its ... up to around 85%. The Packer Protocol has since become a standard treatment for medulloblastoma. Likewise, cisplatin has been ... Platinum-based antineoplastic agents, Platinum(II) compounds, World Health Organization essential medicines, Wikipedia medicine ...
Use under this protocol, usually with fludarabine and melphalan, was developed by oncologists at the University of Texas MD ... Alkylating antineoplastic agents, IARC Group 2A carcinogens, Organochlorides, Cancer treatments, Chloroethyl compounds, ... It is also used as part of a chemotherapeutic protocol in preparation for hematological stem cell transplantation, a type of ...
Antineoplastic drugs may also increase the risk of learning disabilities among children of health care workers who are exposed ... Generating Inhibitors of P-Glycoprotein: Where to, Now?. Springer Protocols. pp. 405-432. Luqmani YA (2005). "Mechanisms of ... In the 1970s, antineoplastic (chemotherapy) drugs were identified as hazardous, and the American Society of Health-System ... A written policy needs to be in place in case of a spill of antineoplastic products. The policy should address the possibility ...
Reilly DR, Delva NJ, Hudson RW (August 2000). "Protocols for the use of cyproterone, medroxyprogesterone, and leuprolide in the ... Hormonal antineoplastic drugs, Ketones, Pregnane X receptor agonists, Pregnanes, Progestogen esters, Progestogens, Prolactin ... Reilly DR, Delva NJ, Hudson RW (August 2000). "Protocols for the use of cyproterone, medroxyprogesterone, and leuprolide in the ... a protocol for reversible medical castration". Urology. 47 (6): 882-884. doi:10.1016/S0090-4295(96)00048-9. PMID 8677581. ...
Acute coronary event protocol is applied and type II can be treated similarly to type I for cardiac symptom control. Glucagon ... anti-neoplastics, glucocorticoids, nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and skin disinfectants. ... In addition to the application of the acute coronary syndrome protocol, thrombus aspiration, and placing a new stent is needed ...
Hormonal antineoplastic drugs, Nonapeptides, Puberty blockers, World Anti-Doping Agency prohibited substances). ... "Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction" (PDF). The Cochrane ...
... with cisplatin or carboplatin as the backbone of all the chemotherapy treatments protocols. Pemetrexed is provided with ... and approved pembrolizumab in combination with pemetrexed and platinum-based antineoplastic (carboplatin or cisplatin) as first ...
... who determined whether the attack met protocol-defined criteria. The trial was conducted at 82 sites in 24 countries (including ... Antineoplastic drugs, Monoclonal antibodies, Orphan drugs). ...
"PROTOCOL FOR THE USE OF ANTIEMETICS TO PREVENT CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING" (PDF). VHA Pharmacy Benefits ... Antineoplastic drugs). ...
The Maputo Protocol, which was adopted by the African Union in the form of a protocol to the African Charter on Human and ... "Antineoplastic (Chemotherapy) Drugs - Reproductive Health , NIOSH , CDC". www.cdc.gov. 2022-02-02. Archived from the original ... "Protocol to the African Charter on Human and Peoples' Rights on the Rights of Women in Africa". Legal Instruments. African ... 2 (a) and (c) of the Protocol to the African Charter on Human and Peoples' Rights on the Rights of Women in Africa". Legal ...
This protocol is likely beneficial in women expected to be hyper-responders, and probably also those expected to be poor ... Hormonal antineoplastic drugs, Human female endocrine system, GnRH antagonists). ... There is probably little or no difference between GnRH antagonist and GnRH agonist protocols in terms of live birth or risk of ... Comparison between a GnRH antagonist and a GnRH agonist flare-up protocol in oocyte donors: a randomized clinical trial. Hum. ...
Controversy remains as to the most effective screening protocols. For example, while some data support decreased mortality ... "Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells". Biochemical ... depending on the duration of diabetes and treatment protocol. A suspected contributor to this increased risk is circulating ...
For certain therapy areas, such as antimicrobials, antineoplastics, antihypertensive and anti-inflammatory drugs, the numbers ... agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis". Bioorganic & Medicinal Chemistry Letters ...
Staurosporine (from S. staurosporeus) also has a range of activities from antifungal to antineoplastic (via the inhibition of ... "Some current Streptomyces Research & Methods / Protocols / Resources". www.openwetware.org. "S. avermitilis genome homepage". ... are antineoplastic (anticancer) drugs; boromycin (from S. antibioticus) exhibits antiviral activity against the HIV-1 strain of ...
Current protocols use the same dosing and treatment protocols for pediatric patents as adult patients. While there are no ... Alkylating antineoplastic agents, IARC Group 2A carcinogens, Nitrosamines, Nitrosoureas, Organochlorides, Cancer treatments, ...
This protocol was performed on the gram-scale without diminishing its yield employing 2-methyl-6-nitrobenzoic anhydride, 4- ... Antineoplastic drugs, Epoxides, Cancer research, Enediynes, Naphthalenes, Experimental drugs, Lactones, Isopropyl compounds, ...
Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug ... Clinical Protocols*Antineoplastic Protocols: 26*Antineoplastic Combined Chemotherapy Protocols: 23*EVAC protocol: 429 ... Protocol, Antineoplastic Chemotherapy; Protocol, Cancer Chemotherapy; Protocols, Antineoplastic Chemotherapy; Protocols, Cancer ... Antineoplastic Chemotherapy Protocol; Antineoplastic Drug Combination; Cancer Chemotherapy Protocol; Chemotherapy Protocol, ...
"Antineoplastic Protocols" by people in this website by year, and whether "Antineoplastic Protocols" was a major or minor topic ... "Antineoplastic Protocols" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... Below are the most recent publications written about "Antineoplastic Protocols" by people in Profiles. ... Below are MeSH descriptors whose meaning is more general than "Antineoplastic Protocols". ...
Oral hygiene protocols reduce the severity and incidence of oral mucositis during antineoplastic treatment: a systematic review ... The objective of this systematic review was to determine whether oral and dental hygiene protocols (DHPs) reduce the incidence ... and severity of oral mucositis (OM) during antineoplastic treatment. MATERIALS AND METHODS:. This PROSPERO-registered ...
Results support the conclusion that the cumulative dose of cisplatin in concurrent chemoradiation protocols for HNSCC has a ... Antineoplastic Combined Chemotherapy Protocols * Carcinoma, Squamous Cell / therapy* * Chemoradiotherapy* * Cisplatin / ... Conclusion: Results support the conclusion that the cumulative dose of cisplatin in concurrent chemoradiation protocols for ... Methods: The absolute survival benefit at 5 years of concurrent chemoradiotherapy protocols versus radiotherapy alone observed ...
Antineoplastic Combined Chemotherapy Protocols, *Canada, *Cancer Care Facilities, *Combined Modality Therapy, *Esophageal ...
Forty infants have subsequently been treated on a protocol incorporating further intensification with an option for hi … ... Antineoplastic Combined Chemotherapy Protocols / therapeutic use* * Bone Marrow Transplantation* * Cytarabine / adverse effects ... Forty infants have subsequently been treated on a protocol incorporating further intensification with an option for high-dose ...
Adenocarcinoma, Mucinous/mortality, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/therapeutic ... Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Carcinoma, Signet Ring Cell/mortality; Chemotherapy, Cancer, ... It is assumed the uniform Dutch HIPEC protocol was beneficial.,/p,}}, author = {{Kuijpers, Anke M J and Mirck, Boj and Aalbers ... Cytoreduction and HIPEC in the Netherlands : nationwide long-term outcome following the Dutch protocol. *Mark ...
Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use) *B-Lymphocytes (drug effects) ...
... antineoplastic combined chemotherapy protocols MeSH E02.190.044.080 - acupressure MeSH E02.190.044.105 - acupuncture analgesia ... antineoplastic combined chemotherapy protocols MeSH E02.319.162.150 - antibiotic prophylaxis MeSH E02.319.300.253 - delayed- ... antineoplastic combined chemotherapy protocols MeSH E02.319.310.075 - antiretroviral therapy, highly active MeSH E02.319. ...
A great number of antineoplastic agents (AAs) are available nowadays, with well-defined therapeutic protocols. The poor ... A great number of antineoplastic agents (AAs) are available nowadays, with well-defined therapeutic protocols. The poor ... Antineoplastics Encapsulated in Nanostructured Lipid Carriers by Gustavo Henrique Rodrigues da Silva ... Ideally, antineoplastic treatment aims to selectively eradicate cancer cells without causing systemic toxicity. ...
Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Diarrhea; Enteritis; Female; ...
Antineoplastic Combined Chemotherapy Protocols, Drug Dosage Calculations, Drug-Related Side Effects and Adverse Reactions, ... Keywords: Area Under Curve, Colorectal Neoplasms, Drug Monitoring, Fluorouracil, Aged, Antimetabolites, Antineoplastic, ...
Antineoplastic Combined Chemotherapy Protocols. *1112 Oncology and Carcinogenesis. Citation. APA Chicago ICMJE ...
Pancreatic Cancer Treatment Protocols * Fast Five Quiz: Do You Know the Risk Factors, Diagnostic Tests, and Treatment for ... Antineoplastic agents. Class Summary. These agents inhibit cell growth and proliferation. They are used for chemotherapy. ... This schema varies among institutions depending on local expertise, research interest, and therapeutic protocols for pancreatic ...
Keywords : Radiotherapy-Adverse effects; Drug therapy-Adverse effects; Antineoplastic protocols; Neoplasms. · abstract in ... The aim of the present work was to present the current oral complications of antineoplastic therapy as well as the importance ... In patients with cancer who have undergone antineoplastic therapy, the development of acute or late oral complications are ...
Antineoplastic Protocols Entry term(s). Antineoplastic Protocol Cancer Treatment Protocol Cancer Treatment Protocols Protocol, ... Antineoplastic Protocol. Cancer Treatment Protocol. Cancer Treatment Protocols. Protocol, Antineoplastic. Protocol, Cancer ... Protocol, Cancer Treatment Protocols, Antineoplastic Protocols, Cancer Treatment Treatment Protocol, Cancer Treatment Protocols ... Protocols, Antineoplastic. Protocols, Cancer Treatment. Treatment Protocol, Cancer. Treatment Protocols, Cancer. Tree number(s ...
keywords = "antineoplastic protocols, chimeric antigen, guidelines as topic, hematological neoplasms, immunotherapy, receptors ...
Palabras clave : emotional stress; breast cancer; antineoplastic chemotherapy protocols. · resumen en Portugués · texto en ...
ANTINEOPLASTIC AGENTS, COMBINED. ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS. D24 - IMMUNOLOGIC AND BIOLOGICAL FACTORS. ...
ANTINEOPLASTIC AGENTS, COMBINED. ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS. D24 - IMMUNOLOGIC AND BIOLOGICAL FACTORS. ...
ANTINEOPLASTIC AGENTS, COMBINED. ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS. D24 - IMMUNOLOGIC AND BIOLOGICAL FACTORS. ...
ANTINEOPLASTIC AGENTS, COMBINED. ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS. D24 - IMMUNOLOGIC AND BIOLOGICAL FACTORS. ...
ANTINEOPLASTIC AGENTS, COMBINED. ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS. D24 - IMMUNOLOGIC AND BIOLOGICAL FACTORS. ...
ANTINEOPLASTIC AGENTS, COMBINED. ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS. D24 - IMMUNOLOGIC AND BIOLOGICAL FACTORS. ...
  • Clinical protocols used to inhibit the growth or spread of NEOPLASMS. (ouhsc.edu)
  • Antineoplastic Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (ouhsc.edu)
  • Forty infants have subsequently been treated on a protocol incorporating further intensification with an option for high-dose chemotherapy and autologous or allogeneic bone marrow transplantation. (nih.gov)
  • PURPOSE: This nationwide study evaluated results of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis of colorectal origin in the Netherlands following a national protocol. (lu.se)
  • The optimal cumulative dose and timing of cisplatin administration in various concurrent chemoradiotherapy protocols for nonmetastatic head and neck squamous cell carcinoma (HNSCC) has not been determined. (nih.gov)
  • The absolute survival benefit at 5 years of concurrent chemoradiotherapy protocols versus radiotherapy alone observed in prospective randomized trials reporting on the use of cisplatin monochemotherapy for nonnasopharyngeal HNSCC was extracted. (nih.gov)
  • Oral hygiene protocols reduce the severity and incidence of oral mucositis during antineoplastic treatment: a systematic review and meta-analysis of randomized and non-randomized clinical trials. (bvsalud.org)
  • The objective of this systematic review was to determine whether oral and dental hygiene protocols (DHPs) reduce the incidence and severity of oral mucositis (OM) during antineoplastic treatment . (bvsalud.org)
  • A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol. (ox.ac.uk)
  • In patients with cancer who have undergone antineoplastic therapy, the development of acute or late oral complications are common. (bvsalud.org)
  • The aim of the present work was to present the current oral complications of antineoplastic therapy as well as the importance of the dentists' performance in this context. (bvsalud.org)
  • Artificial intelligence-assisted selection and efficacy prediction of antineoplastic strategies for precision cancer therapy. (cdc.gov)
  • During an evaluation of the protocol, registered pharmacists, familiar with the use of CSTDs, tested the protocol's prescribed compounding and administration tasks using five commercially available CSTDs. (cdc.gov)
  • A multicenter randomized trial for quality of life evaluation by non-invasive intelligent tools during post-curative treatment follow-up for head and neck cancer: Clinical study protocol. (cdc.gov)
  • The employee questionnaire consisted of a core module (for completion by all employees) addressing broadbased health care issues (e.g., overtime, violence, stress) and 10 targeted hazard modules addressing selected chemical agents (e.g., antineoplastics, sterilants, anesthetics). (cdc.gov)
  • METHODS: In a multi-institutional study prospective databases of patients with peritoneal carcinomatosis (PC) from colorectal cancer and pseudomyxoma peritonei (PMP) treated according to the Dutch HIPEC protocol, a uniform approach for the CRS and HIPEC treatment, were reviewed. (lu.se)
  • Protocol patients did not concurrently receive any other systemic antineoplastic treatment. (elsevierpure.com)
  • 1-5 Antineoplastic treatment was not attempted in any of the cases. (vin.com)
  • An antineoplastic treatment protocol of prednisolone, cytosine arabinoside, and chlorambucil was devised (CGC). (vin.com)
  • published their research of neoantigens in the Nature Protocols, highlighted the advantages of PEAKS software for neoantigens identification. (bioinfor.com)
  • Researchers would be able to customize antineoplastic Protocols for specific patient. (bioinfor.com)
  • This graph shows the total number of publications written about "Antineoplastic Protocols" by people in this website by year, and whether "Antineoplastic Protocols" was a major or minor topic of these publications. (ouhsc.edu)
  • With the additional RFI, NIOSH requested information from the public regarding the feasibility of developing a protocol applicable to CSTDs that use air cleaning or filtration technologies and solicited stakeholders for information on this topic. (cdc.gov)
  • 2-CdA/Cladribine is a synthetic antineoplastic agent for continuous intravenous infusion. (medscape.com)
  • The NIOSH definition of a closed system drug-transfer device (CSTD) was first published in the 2004 NIOSH Alert " Preventing Occupational Exposure to Antineoplastic and Other Hazardous Drugs in Health Care Settings(/niosh/docs/2004-165/default.html) " [DHHS (NIOSH) Publication Number 2004-165]. (cdc.gov)
  • Below are the most recent publications written about "Antineoplastic Protocols" by people in Profiles. (ouhsc.edu)
  • NIOSH does not possess enforcement authority and therefore its recommendations, protocols and guidance do not have the force or effect of law. (cdc.gov)
  • The feasibility of collecting this type of information using a self-administered employee questionnaire in the health services sector was evaluated by pilot-testing paper and web-based modes and selected distribution protocols in a large medical center. (cdc.gov)
  • This article encourages future studies to verify the applicability of oleandrin in antineoplastic therapeutic protocols, human and veterinary medicine, the investigation of antimetastatic properties, as well as the potential increase in patient survival and the decrease of tumor markers. (phoenixbiotechnology.com)
  • or [-iii-] a component in the design of new multi-therapeutic protocols. (oldcitypublishing.com)
  • Clinical protocols used to inhibit the growth or spread of NEOPLASMS . (bvsalud.org)
  • Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. (lookformedical.com)
  • In patients with cancer who have undergone antineoplastic therapy, the development of acute or late oral complications are common. (bvsalud.org)
  • In addition, antineoplastic treatments are given concurrently with adjunct medications to alleviate side effects (such as diphenhydramine for breast cancer), which may independently also impact cognitive function. (biomedcentral.com)
  • Etoposide is a plant alkaloid antineoplastic agent, used in treatment protocols for several types of cancer. (essentialmeds.org)
  • A multicenter randomized trial for quality of life evaluation by non-invasive intelligent tools during post-curative treatment follow-up for head and neck cancer: Clinical study protocol. (cdc.gov)
  • Artificial intelligence-assisted selection and efficacy prediction of antineoplastic strategies for precision cancer therapy. (cdc.gov)
  • Oral hygiene protocols reduce the severity and incidence of oral mucositis during antineoplastic treatment: a systematic review and meta-analysis of randomized and non-randomized clinical trials. (bvsalud.org)
  • The EU Clinical Trials Register currently displays 43691 clinical trials with a EudraCT protocol, of which 7246 are clinical trials conducted with subjects less than 18 years old. (clinicaltrialsregister.eu)
  • This role involves both selection of cooperative group and industry protocols that fit the needs of UF Health's patient population and collaborative efforts with colleagues across multiple disciplines to develop novel institutional initiated trials. (ufhealth.org)
  • We describe a patient with significant, reproducible IgE-mediated adverse reactions to olaparib tablets with implementation of a 1-day desensitization protocol to olaparib capsules, with subsequent successful transition from olaparib capsules to tablets. (biomedcentral.com)
  • The NIOSH definition of a closed system drug-transfer device (CSTD) was first published in the 2004 NIOSH Alert " Preventing Occupational Exposure to Antineoplastic and Other Hazardous Drugs in Health Care Settings(/niosh/docs/2004-165/default.html) " [DHHS (NIOSH) Publication Number 2004-165]. (cdc.gov)
  • Antineoplastic drug exposure in an ambulatory setting: a pilot study. (cdc.gov)
  • BACKGROUND: Exposure to antineoplastic drugs confers health risks to worker s, yet little is known about the exposure after a drug spill, nor has the relationship between exposure and organizational factors such as staffing and work environment been studied. (cdc.gov)
  • CONCLUSIONS: The study protocol successfully captured drug spill reports and biological samples. (cdc.gov)
  • Worker s have detectable levels of antineoplastic drugs through both drug spills and environmental contamination. (cdc.gov)
  • Currently, there is no established 1-day drug desensitization protocol for patients with olaparib type-1 hypersensitivity reactions despite well documented IgE-mediated adverse reactions occurring with olaparib. (biomedcentral.com)
  • To our knowledge, this is the first reported case of successful olaparib desensitization using a novel 1-day desensitization protocol, and will contribute to drug allergy knowledge, in an area where robust data is lacking. (biomedcentral.com)
  • The objective of this systematic review was to determine whether oral and dental hygiene protocols (DHPs) reduce the incidence and severity of oral mucositis (OM) during antineoplastic treatment . (bvsalud.org)
  • La mucositis oral (MO) representa una afección inflamatoria frequente em pacientes oncológicos e uma higiene oral insatisfatória tem frecuente en pacientes con cáncer, y la mala higiene bucal se ha relacionado sido relacionada como fator predisponente para o seu surgimento. (bvsalud.org)
  • Trata-se de um estudo-piloto clínico hygiene oral rigurosa en la prevención de la MO. (bvsalud.org)
  • O clínico piloto aleatorizado, en el que treinta y cinco pacientes fueron asignados grupo-caso foi submetido ao controle de higiene oral associado ao uso en dos grupos. (bvsalud.org)
  • We report a 58-year-old female with immediate, reproducible IgE-mediated adverse reactions to olaparib tablets with implementation of a 1-day novel desensitization protocol to olaparib. (biomedcentral.com)
  • The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announced the availability of the following draft document for public comment entitled A Vapor Containment Performance Protocol for Closed System Transfer Devices Used During Pharmacy Compounding and Administration of Hazardous Drugs. (cdc.gov)
  • Preliminary report from the national protocol on antineoplastic drugs]. (nih.gov)
  • Four participants who reported a spill showed detectable levels of antineoplastic drugs. (cdc.gov)
  • Safety analysis was per protocol. (ox.ac.uk)
  • A panel consisting of peer reviewers and stakeholders was asked to review and comment on the draft guidance document and protocol. (cdc.gov)
  • NIOSH does not possess enforcement authority and therefore its recommendations, protocols and guidance do not have the force or effect of law. (cdc.gov)
  • This protocol was made public as a draft to solicit comments from the public and should not be cited as if it were a published final agency position. (cdc.gov)